Browse C5

Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00207 Alpha-2-macroglobulin family
PF07678 A-macroglobulin complement component
PF01835 MG2 domain
PF07703 Alpha-2-macroglobulin family N-terminal region
PF07677 A-macroglobulin receptor
PF01821 Anaphylotoxin-like domain
PF01759 UNC-6/NTR/C345C module
Function

Activation of C5 by a C5 convertase initiates the spontaneous assembly of the late complement components, C5-C9, into the membrane attack complex. C5b has a transient binding site for C6. The C5b-C6 complex is the foundation upon which the lytic complex is assembled.; FUNCTION: Derived from proteolytic degradation of complement C5, C5 anaphylatoxin is a mediator of local inflammatory process. Binding to the receptor C5AR1 induces a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:8182049). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0001525 angiogenesis
GO:0001701 in utero embryonic development
GO:0001819 positive regulation of cytokine production
GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002526 acute inflammatory response
GO:0002673 regulation of acute inflammatory response
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002686 negative regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002689 negative regulation of leukocyte chemotaxis
GO:0002697 regulation of immune effector process
GO:0002920 regulation of humoral immune response
GO:0006956 complement activation
GO:0006957 complement activation, alternative pathway
GO:0006958 complement activation, classical pathway
GO:0006959 humoral immune response
GO:0009306 protein secretion
GO:0010466 negative regulation of peptidase activity
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010575 positive regulation of vascular endothelial growth factor production
GO:0010758 regulation of macrophage chemotaxis
GO:0010760 negative regulation of macrophage chemotaxis
GO:0010951 negative regulation of endopeptidase activity
GO:0016064 immunoglobulin mediated immune response
GO:0016485 protein processing
GO:0019724 B cell mediated immunity
GO:0019835 cytolysis
GO:0030336 negative regulation of cell migration
GO:0030449 regulation of complement activation
GO:0030595 leukocyte chemotaxis
GO:0032102 negative regulation of response to external stimulus
GO:0032147 activation of protein kinase activity
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0033674 positive regulation of kinase activity
GO:0040013 negative regulation of locomotion
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045860 positive regulation of protein kinase activity
GO:0045861 negative regulation of proteolysis
GO:0048246 macrophage chemotaxis
GO:0048514 blood vessel morphogenesis
GO:0050663 cytokine secretion
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050715 positive regulation of cytokine secretion
GO:0050727 regulation of inflammatory response
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050922 negative regulation of chemotaxis
GO:0051047 positive regulation of secretion
GO:0051222 positive regulation of protein transport
GO:0051271 negative regulation of cellular component movement
GO:0051346 negative regulation of hydrolase activity
GO:0051604 protein maturation
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060326 cell chemotaxis
GO:0070613 regulation of protein processing
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072376 protein activation cascade
GO:0090195 chemokine secretion
GO:0090196 regulation of chemokine secretion
GO:0090197 positive regulation of chemokine secretion
GO:0097529 myeloid leukocyte migration
GO:1901342 regulation of vasculature development
GO:1903317 regulation of protein maturation
GO:1903532 positive regulation of secretion by cell
GO:1904018 positive regulation of vasculature development
GO:1904951 positive regulation of establishment of protein localization
GO:2000146 negative regulation of cell motility
GO:2000257 regulation of protein activation cascade
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0004857 enzyme inhibitor activity
GO:0004866 endopeptidase inhibitor activity
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0030414 peptidase inhibitor activity
GO:0042379 chemokine receptor binding
GO:0061134 peptidase regulator activity
GO:0061135 endopeptidase regulator activity
Cellular Component GO:0005579 membrane attack complex
GO:0046930 pore complex
> KEGG and Reactome Pathway
 
KEGG hsa04610 Complement and coagulation cascades
Reactome R-HSA-174577: Activation of C3 and C5
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-166658: Complement cascade
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-977606: Regulation of Complement cascade
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-166665: Terminal pathway of complement
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between C5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between C5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23028051Lung carcinomaInhibit immunityC5a also contributed to the immunosuppressive microenvironment required for tumor growth. In particular, blockade of C5a receptor significantly reduced myeloid-derived suppressor cells and immunomodulators ARG1, CTLA-4, IL-6, IL-10, LAG3, and PDL1 (B7H1). In conclusion, lung cancer cells have the capacity to generate C5a, a molecule that creates a favorable tumor microenvironment for lung cancer progression.
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of C5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of C5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1380.811
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.1440.234
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)871.0710.192
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4010.256
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8460.574
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1620.933
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1610.76
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.4720.659
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2630.833
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3730.761
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9410.197
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.120.436
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of C5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of C5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of C5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by C5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of C5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of C5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between C5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolC5
Namecomplement component 5
Aliases CPAMD4; C5b; prepro-C5; C5a anaphylatoxin; C5Da; ECLZB; C3 and PZP-like alpha-2-macroglobulin domain-contain ......
Chromosomal Location9q33-q34
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting C5 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting C5.
ID Name Drug Type Targets #Targets
DB00028Immune Globulin HumanBiotechC3, C4A, C4B, C5, FCGR1A, FCGR1B, FCGR2A, FCGR2B, FCGR2C, FCGR3A, ......11
DB01257EculizumabBiotechC51
DB01593ZincSmall MoleculeA1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......119
DB09130CopperSmall MoleculeA1BG, ACTG1, ACTN1, ACY1, AFM, AGT, AHCY, AHSG, AKR1A1, ANXA4, ANX ......141